The Wall Street Journal reports:
An experimental Covid-19 vaccine from Novavax was 90.4% effective at preventing symptomatic disease in adults in a large clinical trial, the company said, results that move the shot a step closer to global use.
The 29,960-person study conducted in the U.S. and Mexico also found that the vaccine was similarly effective against newer coronavirus strains, especially the alpha variant now dominant in the U.S., Novavax said.
The vaccine, given in two doses three weeks apart, was also generally safe and well tolerated in the study, the company said. “Our vaccine works very well even though the virus has mutated significantly,” said Dr. Gregory Glenn, Novavax’s president of research and development.
Read the full article.
The vaccine is easier to store and transport, which could make Novavax a key player in getting access to shots in the developing world.
— Tampa Bay Times (@TB_Times) June 14, 2021